Bioavailability of lenvatinib administered as a capsule or tablet in volunteers

Trial Profile

Bioavailability of lenvatinib administered as a capsule or tablet in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2014

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Endometrial cancer; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 19 Feb 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
    • 19 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 19 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top